Literature DB >> 6174616

Molecular relationships of the human B cell alloantigens, MT2, MB3, MT4, and DR5.

R W Karr, C C Kannapell, J A Stein, H M Gebel, D L Mann, R J Duquesnoy, T C Fuller, G E Rodey, B D Schwartz.   

Abstract

The human class II, HLA-linked, B cell alloantigens include the HLA-DR, MB, MT, and Te determinants. Interest in the molecular relationships of these antigens has recently intensified because of their homology to the murine Ia antigens and their possible importance in disease predisposition and transplantation. We have used alloantisera with carefully defined immunochemical as well as serologic specificity, and two immunochemical techniques, sequential immunoprecipitation with analysis by SDS-PAGE and two-dimensional gel electrophoresis, to explore the molecular relationships of the MT2, MB3, MT4, and HLA-DR5 antigenic determinants. The data presented here indicate that 1) all class II molecules that bear the DR5 antigenic determinant also bear the MT2 antigenic determinant; (2) the homozygous DR5 cell line, Swei, expresses at least two structurally distinct class II molecules, both of which bear MT2: one bears the MT2, MB3, and MT4 antigenic determinants, and the second bears the MT2, but not the MB3 or MT4 antigenic determinant; and (3) the DR5 determinant is located on at least one and possibly both of these distinct class II molecules.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Polymorphisms within the HLA-DRw6 haplotype. II. Protein charge heterogeneity reflects MLC subtyping of HLA-DRw6 homozygous cells.

Authors:  M L Bosch; A Termijtelen; R Gerrets; G M Schreuder; R E Bontrop; M J Giphart
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  Correlation between an HLA-DQ alpha length polymorphism of messenger RNA and serologically defined specificities (DQw1, DRw53, DR3+5).

Authors:  P Loiseau; P Lehn; F Dautry; V Lepage; J Colombani; D Cohen; J Dausset; L Degos
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.

Authors:  F M Brodsky
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

4.  Evidence for polymorphism of MB3 antigens among three HLA-D clusters associated with HLA-DR4.

Authors:  H Ikeda; M Kasahara; K Ogasawara; T Takenouchi; T Okuyama; N Ishikawa; A Wakisaka; Y Kikuchi; M Aizawa
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

5.  HLA-DR7-specific monoclonal antibodies and a chimpanzee anti-DR7 serum detect different epitopes on the same molecule.

Authors:  S F Radka; D B Amos; L J Quackenbush; P Cresswell
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

6.  Antigen-specific HLA-restricted human T-cell lines. I. An MT3-like restriction determinant distinct from HLA-DR.

Authors:  E J Ball; P Stastny
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

7.  Association of PLT specificity of alloreactive lymphocyte clones with HLA-DR, MB and MT determinants.

Authors:  A Zeevi; C Scheffel; K Annen; G Bass; M Marrari; R J Duquesnoy
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

8.  Characterization of human helper and suppressor factors with special reference to HLA-DR determinants.

Authors:  T Lehner
Journal:  Immunology       Date:  1983-04       Impact factor: 7.397

9.  Primed lymphocyte testing specificity of alloreactive lymphocyte clones for HLA-B locus determinants.

Authors:  A Zeevi; C Scheffel; K Annen; R J Duquesnoy
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

10.  Homogeneity of the HLA-linked SB2 and SB3 specificities demonstrated by cloned alloreactive T cells.

Authors:  G Pawelec; S Shaw; M Schneider; A Rehbein; P Wernet
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.